BT-PROTAC
BT-PROTAC is a bioorthogonally activatable BRD4/BRD3 PROTAC degrader prodrug. BT-PROTAC is inactive when present alone, but upon activation by tetrazine compounds, it promotes the degradation of BRD4 and BRD3 via the ubiquitin-proteasome system, inhibits c-Myc expression, activates caspase-3, and induces apoptosis in breast cancer cells. BT-PROTAC can be used for breast cancer research.
(Pink: BRD4 and BRD3 ligand (HY-13030); Blue: VHL ligand (HY-125845); Black: linker (HY-140189)).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3032848-64-6
- Formule: C59H74ClN9O10S2
- Masse moléculaire:1168.86
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform PROTACs
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
Description
IC50 & Target
[1]|
BRD4 |
BRD3 |
VHL |
Caspase 3 |
In Vitro
BT-PROTAC (48 h) exhibits low cytotoxicity when acting alone on T47D breast cancer cells, with an IC50 of 1761.0 nM; however, its cytotoxicity is restored after pre-incubation with BODIPY-TZ, and the IC50 decreases to 407.0 nM[1].
BT-PROTAC (48 h) exhibits low cytotoxicity when acting alone on MDA-MB-231 breast cancer cells, with an IC50 of 652.2 nM; however, its cytotoxicity is restored after pre-incubation with BODIPY-TZ, and the IC50 decreases to 326.5 nM[1].
BT-PROTAC (48 h) exhibits low cytotoxicity when applied alone to MCF-7 breast cancer cells, with an IC50 of 1319.0 nM; however, its cytotoxicity is restored after pre-incubation with BODIPY-TZ, and the IC50 decreases to 263.6 nM[1].
BT-PROTAC (0-2.0 μM; 48 h) alone does not degrade BRD4 or BRD3 in T47D, MB-231, and MCF-7 breast cancer cells even at concentrations as high as 2.0 μM, but achieves degradation of BRD4 and BRD3 via the ubiquitin-proteasome system after pre-incubation with BODIPY-TZ[1].
After activation by BODIPY-TZ, BT-PROTAC (48 h) inhibits c-Myc expression and activates caspase-3 in T47D, MDA-MB-231 and MCF-7 breast cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:T47D, MDA-MB-231 and MCF-7 breast cancer cells
-
Concentration:0, 0.2, 0.4, 0.8, 1 and 2 μM (BT-PROTAC alone); 0, 25, 100, 200, 400 and 1000 nM (BT-PROTAC after 20.0 μM BODIPY-TZ preincubation)
-
Incubation Time:48 h (BT-PROTAC incubation); 12 h (BODIPY-TZ preincubation)
-
Result:Did not degrade BRD4 or BRD3 at concentrations up to 2.0 μM when used alone.
Significantly reduced BRD4 and BRD3 protein levels when combined with BODIPY-TZ.
Had its degradation effect blocked by 10.0 μM MG132 (HY-13259) or 3.0 μM MLN4924 (HY-70062), confirming dependence on the ubiquitin-proteasome system.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (female, 6-8 weeks old)[1]
-
Dosage:20 mg/kg (preceded by 50 mg/kg IR808-TZ 2 hours earlier)
-
Administration:i.v.; single administration
-
Result:Reduced tumor volume increase to 1.74-fold at 23 days post-injection, compared to 5.98-fold in the BT-PROTAC-only group and 6.32-fold in the PBS group.
Significantly reduced tumor weight compared to PBS and BT-PROTAC-only groups.
Significantly reduced BRD4 protein levels in tumor tissue, while BT-PROTAC alone had negligible effect on BRD4 levels.
Induced obvious apoptosis via cleaved caspase-3 staining, with no apoptosis signal detected in the BT-PROTAC-only group.
Significantly inhibited tumor cell proliferation via Ki67 staining compared to BT-PROTAC-only and PBS groups.
Chemical Information
-
CAS No. 3032848-64-6
-
Masse moléculaire 1168.86
-
Formule C59H74ClN9O10S2
-
SMILES
O=C([C@@H](NC(COCCOCCOCCNC(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(C)S3)C)=O)=O)C(C)(C)C)N5[C@@H](C[C@H](C5)OC(OC6CCCCC/C=C/6)=O)C(N[C@H](C7=CC=C(C=C7)C8=C(N=CS8)C)C)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)